17th Annual BIO CEO & Investor Conference to Feature Congressional Leaders, Institutional Investors, Industry Analysts and Senior Biotechnology Executives
CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million
Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET® sNDA for Use in Adolescent Patients
Research and Markets: Myanmar Healthcare Report: A Look Into Myanmar's Emerging $480 Million Healthcare Sector
Research and Markets: Brazil Pharmaceutical Market Outlook 2018
Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.
Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Top managers continue to find new opportunities, while taking full advantage of a rising stock market to book some gains.